Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Medline Industries’ Recall of Non-Sterile Saline Solution Vials Deemed Class 1 By FDA

  • Post author:PacConAdmin
  • Post published:September 21, 2023
  • Post category:Uncategorized

Medline Industries’ recall of 18,000 saline solution vials due to being non-sterile has been deemed as class 1 by the FDA, the most serious type of recall, because use of…

Continue ReadingMedline Industries’ Recall of Non-Sterile Saline Solution Vials Deemed Class 1 By FDA

Lilly Becomes Second Maker of GLP-1 Inhibitors to File Lawsuits Against Copycats

  • Post author:PacConAdmin
  • Post published:September 21, 2023
  • Post category:Uncategorized

Eli Lilly has filed 10 patent lawsuits against wellness clinics, med spas and compounders and pharmacies for marketing and selling unapproved versions of the company’s blockbuster Type 2 diabetes drug,…

Continue ReadingLilly Becomes Second Maker of GLP-1 Inhibitors to File Lawsuits Against Copycats

Meeting Requests, Manufacturer Assessments for NDAs and BLAs Subject of Draft Guidances

  • Post author:PacConAdmin
  • Post published:September 21, 2023
  • Post category:Uncategorized

The FDA has issued two draft guidances focused on requirements for drug and biological approvals — one on formal meetings and one on alternative methods the agency may use to…

Continue ReadingMeeting Requests, Manufacturer Assessments for NDAs and BLAs Subject of Draft Guidances

FDA’s Pediatric Advisors: Artificial Womb Technology Not Yet Ready for Human Trials

  • Post author:PacConAdmin
  • Post published:September 20, 2023
  • Post category:Uncategorized

Much needs to be hammered out before the FDA can comfortably green light first-in-human studies of artificial womb devices for extremely premature infants, said several members of the FDA’s Pediatric…

Continue ReadingFDA’s Pediatric Advisors: Artificial Womb Technology Not Yet Ready for Human Trials

FDA Broadens Pandemic-Era Guidance to Cover Trials During PHEs, Disasters

  • Post author:PacConAdmin
  • Post published:September 20, 2023
  • Post category:Uncategorized

The FDA has expanded the scope of its guidance on conducting clinical trials during the COVID-19 pandemic to apply to public health emergencies (PHE) and other disasters, issuing final guidance…

Continue ReadingFDA Broadens Pandemic-Era Guidance to Cover Trials During PHEs, Disasters

neffy Nasal Spray Alternate for EpiPen Gets CRL Despite AdComm Endorsement

  • Post author:PacConAdmin
  • Post published:September 20, 2023
  • Post category:Uncategorized

ARS Pharmaceuticals announced that the FDA issued a complete response letter (CRL) on its NDA for neffy (epinephrine nasal spray) after having received a recommendation for approval from the agency’s…

Continue Readingneffy Nasal Spray Alternate for EpiPen Gets CRL Despite AdComm Endorsement

CDRH Plan Aims for Harmonized International Device Regulations, Policies, Practices

  • Post author:PacConAdmin
  • Post published:September 20, 2023
  • Post category:Uncategorized

CDRH, as part of its MDUFA V commitments, has released a draft plan to further its work toward globally harmonized medical device regulation, policy and practices as part of the…

Continue ReadingCDRH Plan Aims for Harmonized International Device Regulations, Policies, Practices

Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

  • Post author:PacConAdmin
  • Post published:September 20, 2023
  • Post category:Uncategorized

Despite impressive gains in recent years, investment in gene therapy products is at a critical juncture due to current manufacturing challenges, among other factors, says Peter Marks, director of CBER,…

Continue ReadingManufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

CDER’s Cavazzoni Warns Drug Shortages Becoming More Complex

  • Post author:PacConAdmin
  • Post published:September 19, 2023
  • Post category:Uncategorized

While the U.S. has seen a decrease in the number of shortages, the country has seen an increase in the complexity of shortages and the time necessary to mitigate these…

Continue ReadingCDER’s Cavazzoni Warns Drug Shortages Becoming More Complex

FDA Dep. Director Says AI/ML Data Collection Needs to Avoid Bias

  • Post author:PacConAdmin
  • Post published:September 19, 2023
  • Post category:Uncategorized

Applications that use AI and machine learning (ML) have a unique dependence on data, said the FDA’s Digital Health Center of Excellence Acting Deputy Director MiRa Jacobs at Tuesday’s open…

Continue ReadingFDA Dep. Director Says AI/ML Data Collection Needs to Avoid Bias
  • Go to the previous page
  • 1
  • …
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company